Epidermolysis Bullosa
Epidermolysis Bullosa Market

Epidermolysis Bullosa is a group of skin diseases, which cause several degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins vital for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma.

 

The symptoms of Epidermolysis Bullosa can vary depending on its type and usually appear when an affected person is a baby or toddler. Some types of Epidermolysis Bullosa have a low risk of serious complications, but other types can be life-threatening.  


Epidermolysis Bullosa Epidemiological Segmentation 

The Epidemiological Segmentation of Epidermolysis Bullosa in 7MM from 2017 to 2030 is segmented as:- 

  • Total Prevalent Cases of Epidermolysis Bullosa
  • Diagnosed Prevalence of Epidermolysis Bullosa 
  • Type-specific Diagnosed Prevalence of Epidermolysis Bullosa 


Epidermolysis Bullosa Epidemiology 

  • The total prevalent population of Epidermolysis Bullosa in 7MM in 2017 was 41,509  
  • The prevalent cases of Epidermolysis Bullosa in the United States were 26,104 in 2017 


Epidermolysis Bullosa Market

The market size of Epidermolysis Bullosa in 7MM in 2017 was USD 2,283.40 million 


Epidermolysis Bullosa Market Drivers

  • Robust pipeline 
  • Increase in funding for accelerating the development of novel therapies for Epidermolysis Bullosa treatment
  • Encouraging organizations to develop promising therapies 


Epidermolysis Bullosa Market Barriers

  • Challenges in Epidermolysis Bullosa diagnosis
  • Lack of awareness
  • High Cost of Epidermolysis Bullosa treatment and management 


Epidermolysis Bullosa Emerging Drugs

The emerging drugs of the Epidermolysis Bullosa market are 

  • Oleogel-S10 (AP-101)
  • EB-101
  • CCP-020 (Diacerein 1% Ointment)
  • RGN-137
  • B-VEC (KB103, Beremagene Geperpavec)
  • FCX-007
  • Allo-APZ2-EB 
  • COL7 and LAMB3 gene therapy 
  • KOI2 (Redasemtide/HMGB1 Peptides)
  • PTR-01 (BBP-589): Serlopitant (VPD-737)

And many others.  

 

Epidermolysis Bullosa Key Players

The key players in the Epidermolysis Bullosa market are

  • Amryt Pharma
  • Abeona Therapeutics
  • Castle Creek Pharmaceuticals
  • RegeneRx
  • Krystal Biotech
  • Fibrocell Technologies
  • Castle Creek Pharmaceuticals
  • RHEACELL GmbH
  • Holostem Terapie Avanzate
  • StemRim
  • Shionogi
  • Phoenix Tissue Repair (BridgeBio Pharma, Inc)
  • Menlo Therapeutics 

And many others.